Benign breast disease
- PMID: 20733462
- DOI: 10.1097/AOG.0b013e3181ee9fc7
Benign breast disease
Abstract
Benign breast diseases are among the most common diagnoses that the busy obstetrician-gynecologist will see in practice. Moreover, breast cancer will undoubtedly be diagnosed numerous times in an obstetrician-gynecologist's career. An ability to accurately and promptly diagnose both benign and malignant breast diseases is within the purview of the generalist obstetrician-gynecologist. A thorough understanding of benign breast diseases, including appropriate diagnostic techniques, is vitally important in well-women care. In addition, a working knowledge of breast cancer risk factors with the ability to identify women at high risk and either refer or initiate risk reduction methods is equally important. This review outlines common benign breast diseases stratified by future risk of breast cancer and discusses appropriate management after diagnosis.
Similar articles
-
Practice Bulletin No. 164 Summary: Diagnosis and Management of Benign Breast Disorders.Obstet Gynecol. 2016 Jun;127(6):1181-1183. doi: 10.1097/AOG.0000000000001476. Obstet Gynecol. 2016. PMID: 27214183
-
Practice Bulletin No. 164: Diagnosis and Management of Benign Breast Disorders.Obstet Gynecol. 2016 Jun;127(6):e141-e156. doi: 10.1097/AOG.0000000000001482. Obstet Gynecol. 2016. PMID: 27214189
-
Role of the obstetrician/gynecologist in the management of breast disease.Obstet Gynecol Clin North Am. 1994 Sep;21(3):421-31. Obstet Gynecol Clin North Am. 1994. PMID: 7816403 Review.
-
Benign breast disorders.Obstet Gynecol Clin North Am. 2013 Sep;40(3):459-73. doi: 10.1016/j.ogc.2013.05.004. Epub 2013 Jul 24. Obstet Gynecol Clin North Am. 2013. PMID: 24021252 Review.
-
Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer.J Clin Oncol. 2015 Oct 1;33(28):3137-43. doi: 10.1200/JCO.2015.60.8869. Epub 2015 Aug 17. J Clin Oncol. 2015. PMID: 26282663 Free PMC article.
Cited by
-
Detection rate of breast malignancy of needle localization biopsy of breast microcalcification.Tzu Chi Med J. 2021 Mar 22;33(3):275-281. doi: 10.4103/tcmj.tcmj_191_20. eCollection 2021 Jul-Sep. Tzu Chi Med J. 2021. PMID: 34386366 Free PMC article.
-
Correlation Between Body Mass Index and Fibroadenoma.Cureus. 2019 Jul 23;11(7):e5219. doi: 10.7759/cureus.5219. Cureus. 2019. PMID: 31565622 Free PMC article.
-
The long non coding RNA H19 as a biomarker for breast cancer diagnosis in Lebanese women.Sci Rep. 2020 Dec 17;10(1):22228. doi: 10.1038/s41598-020-79285-z. Sci Rep. 2020. PMID: 33335214 Free PMC article.
-
A comparison of hormonal profiles between breast cancer and benign breast disease: a case-control study.Ann Oncol. 2013 Oct;24(10):2527-2533. doi: 10.1093/annonc/mdt207. Epub 2013 May 30. Ann Oncol. 2013. PMID: 23723293 Free PMC article.
-
Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study.Cancer Prev Res (Phila). 2014 Feb;7(2):211-7. doi: 10.1158/1940-6207.CAPR-13-0222. Epub 2014 Jan 30. Cancer Prev Res (Phila). 2014. PMID: 24480577 Free PMC article.
References
-
- American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins—Gynecology, ACOG Committee of Genetics, Society of Gynecologic Oncologist. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009;113:957–66.
-
- Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36–47.
-
- Anderson G, Limacher M, Assaf A, Bassford T, Beresford SAA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12.
-
- Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33.
-
- Heiss G, Wallace R, Anderson G, Aragaki A, Beresford SAA, Brzyski R, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036–45.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical